Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines-Reference-Cited by-同舟云学术

Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines

Published:2012-06-01 Issue:6 Volume:97 Page:E898-E906
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Piscazzi Annamaria¹,Costantino Eleonora¹,Maddalena Francesca²,Natalicchio Maria Iole³,Gerardi Assunta Maria Teresa¹,Antonetti Raffaele³,Cignarelli Mauro⁴,Landriscina Matteo¹

Affiliation:

1. Clinical Oncology Unit (A.P., E.C., A.M.T.G., M.L.), 71122 Foggia, Italy

2. Laboratory of Pre-clinical and Translational Research, Instituto di Ricovero e Cura a Carattere Scientifico-Centro di Riferimento Oncologico Regionale della Basilicata (F.M.), 85028 Rionero in Vulture, Italy

3. Molecular Biology Laboratory (M.I.N., R.A.), Azienda Ospedali Riuniti, Foggia, Italy

4. Department of Medical Sciences, and Endocrinology Unit (M.C.), Department of Medical Sciences, University of Foggia, 71122 Foggia, Italy

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/97/6/E898/10747935/jcemE898.pdf

Reference34 articles.

1. New therapeutic approaches for metastatic thyroid carcinoma.;Baudin;Lancet Oncol,2007

2. Differentiated thyroid cancer.;Burns;Semin Oncol,2010

3. New treatment modalities in advanced thyroid cancer.;Kapiteijn;Ann Oncol,2012